ArticleEuropean radiology experimental2026
7-T MRI intratumoral susceptibility signals reflect biomarker status in gliomas.
Article in European radiology experimental, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveTo evaluate whether 7-T susceptibility-weighted imaging (SWI) can predict glioma's histological grade, Ki-67 labeling index (LI), isocitrate dehydrogenase 1 (IDH1) mutation, 1p/19q co-deletion, telomerase reverse transcriptase (TERT) promoter mutation, and O-6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status of gliomas. MATERIALS AND
methodsWe retrospectively analyzed 7-T SWI in 60 patients with glioma. The Mann-Whitney U test compared the intratumoral susceptibility signals (ITSS) grade across molecular markers, with ITSS defined as fine linear or dot-like low signal areas on SWI. Predictive efficacy was assessed using receiver operating characteristic (ROC) analysis and multivariate logistic regression models. Path analysis evaluated the relationships between ITSS grade and molecular markers.
resultsGliomas with high ITSS grade showed higher histological grade, Ki-67 LI, and TERT mutation rates compared to those with low ITSS grade, mostly being wild-type gliomas. ITSS grade predicted the histological grade, Ki-67 LI, and TERT status (area under the ROC curve = 0.769‒0.817). Multivariate logistic regression analysis identified Ki-67 LI and TERT status as independent predictors of high ITSS grade. Path analysis indicated direct effects of Ki-67 LI and TERT mutation on ITSS grade, and an indirect effect of IDH1 mutation on ITSS grade mediated through Ki-67 LI.
conclusion7-T SWI-derived ITSS grade predicts histologic grade, Ki-67 LI, and TERT promoter mutation status in gliomas. Ki-67 LI and TERT mutation exert relatively independent effects on ITSS grade and allow reverse inference of their status from SWI, whereas IDH1 mutation influences ITSS grade indirectly via Ki-67 LI. RELEVANCE STATEMENT: This study establishes a connection between preoperative imaging and molecular glioma pathology via 7-T SWI. It helps to reveal the in vivo characteristics of pathology and promotes collaboration among radiologists, pathologists, and clinicians, which a great clinical potential. KEY POINTS: A 7-T susceptibility-weighted MRI-based intratumoral susceptibility signal (ITSS) grading system enables precise detection of glioma microbleeds and neovascularization. 7-T susceptibility-weighted MRI-derived ITSS grade noninvasively predicts histologic grade, Ki-67 labeling index, and telomerase reverse transcriptase (TERT) promoter mutation status in gliomas. Path analysis suggested that molecular markers relate to ITSS grade through distinct pathways, with Ki-67 and TERT exerting direct effects and isocitrate dehydrogenase 1 influencing ITSS grade indirectly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.